The Seeking Alpha author plainly doesn’t understand GILD’s HIV franchise:
Viread is rarely used as a standalone product, but it’s the foundation—along with Emtriva—of all of GILD’s big-selling HIV cocktails. Inasmuch as GILD’s Emtriva patents running beyond 2017 are suspect and have already been challenged, the loss of patent protection on Viread in 2017 could open the door for generic versions of Truvada and hence is a much more serious matter for GILD than the Seeking Alpha author realizes.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.